Antisense Pharma investors put in further €8 million as founder CEO steps aside
This article was originally published in Scrip
Executive Summary
Antisense Pharma of Germany has raised €8 million from existing investors MIG Funds and Global Asset Fund. In addition, its co-founder and CEO Dr Karl-Hermann Schlingensiepen is stepping aside as CEO and will now act as a 'strategic consultant' to the company. Dr Schlingensiepen and the investors "developed this solution together", according to the company.